As part of its long-term effort to improve access to its technology, Abbott is trying to reduce barriers to participation in clinical trials, especially for groups of people who have traditionally been underrepresented in clinical trials and underserved by medical technology.
About 40% of the US population is a member of an historically underrepresented demographic group, but multiple studies have shown...